IN8bio expands capabilities with opening of development facility in AL

IN8bio announced the grand opening of its advanced research and development facility in Birmingham, AL. Spanning 10,000 square feet, the state-of-the-art facility will complement IN8bio’s current GMP manufacturing spaces and bolster the Company’s preclinical, clinical, and process development capabilities to advance its groundbreaking pipeline of gamma-delta T cell therapies. To celebrate this milestone, IN8bio will host a grand opening event on August 10th, uniting investors, supporters, collaborators, local officials, and biotechnology leaders. “This new facility underscores our commitment to Birmingham, the local scientific talent and the community,” said William Ho, CEO and co-founder of IN8bio. “IN8bio’s journey began in Birmingham, and we are excited to expand our footprint where we can benefit from the rich cancer research heritage driven by the University of Alabama at Birmingham. We are very appreciative of the support we have received from our local partners, investors, Sloss Real Estate and the City of Birmingham in the establishment of our new R&D laboratory. This facility will play an important role in our growth as we strive towards our mission of achieving “Cancer Zero,” leveraging the power of the immune system to develop therapies to eradicate cancer.”